XOMA Royalty (XOMA) Competitors

Innoviva (NASDAQ:INVA) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Does the media favor INVA or XOMA?

In the previous week, XOMA Royalty had 1 more articles in the media than Innoviva. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for Innoviva. XOMA Royalty's average media sentiment score of 0.74 beat Innoviva's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the news media.

Company	Overall Sentiment
Innoviva	Neutral
XOMA Royalty	Positive

Which has more risk and volatility, INVA or XOMA?

Innoviva has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Do analysts recommend INVA or XOMA?

Innoviva presently has a consensus target price of $55.00, suggesting a potential upside of 190.85%. XOMA Royalty has a consensus target price of $69.50, suggesting a potential upside of 165.57%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
XOMA Royalty	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in INVA or XOMA?

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 2.3% of Innoviva shares are held by insiders. Comparatively, 9.1% of XOMA Royalty shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has stronger valuation and earnings, INVA or XOMA?

Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$358.71M	3.31	$23.39M	-$1.01	-18.72
XOMA Royalty	$13.05M	24.00	-$13.82M	-$1.15	-22.76

Is INVA or XOMA more profitable?

XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	-16.15%	15.77%	8.41%
XOMA Royalty	-13.04%	-12.43%	-4.85%

Summary

Innoviva beats XOMA Royalty on 8 of the 14 factors compared between the two stocks.